EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rivaroxaban Use for Central Nervous System Thrombotic Events in Neonates: A Case Series

Domenico Umberto De Rose, Valerio Romano, Sara Ronci, Chiara Maddaloni, Roberta Arena, Daniela Longo, Matteo Luciani, Annabella Braguglia, Andrea Dotta, Francesca Gallini, Francesca Campi

Children · 19.11.2026 · 13 (11) · 1611

DOI: 10.3390/children13111611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Children, online erschienen am 19.11.2026. Verfasst von Domenico Umberto De Rose und 10 weiteren Autor:innen. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Central nervous system (CNS) thrombotic events in neonates are a rare but severe condition. Evidence on the use of direct oral anticoagulants in this population is extremely limited, and rivaroxaban use remains off label.

Objectives

To describe the safety and effectiveness outcomes of rivaroxaban use in neonates with CNS thrombotic events.

Methods

We conducted a retrospective case series including all neonates treated with rivaroxaban for CNS thrombotic events in two tertiary neonatal intensive care units between January and December 2025. Clinical, laboratory, thrombophilia screening, treatment, imaging, and outcome data were retrospectively collected. Rivaroxaban was administered as an oral suspension (Xarelto®, 1 mg/mL) following initial parenteral anticoagulation. We reported effectiveness and safety outcomes.

Results

Six term neonates were included. Rivaroxaban was initiated between 13 and 31 days of life using weight-based dosing. Maternal or perinatal risk factors were identified in five cases, while thrombophilia screening revealed heterogeneous and isolated abnormalities without a consistent inherited prothrombotic profile. Among six neonates with adequate imaging follow-up, complete thrombus resolution was documented in three cases and partial resolution in two cases, with no thrombus progression or recurrence. One neonate showed imaging evolution related to the initial cerebral injury without documented thrombus resolution. One minor bleeding event occurred (a transient conjunctival bleeding), without need for treatment modification. No major bleeding events, treatment interruptions, or deaths were observed.

Conclusions

In this neonatal case series, off-label rivaroxaban use for CNS thrombosis was feasible and generally well tolerated, with favorable effectiveness outcomes in patients on available neuroimaging follow-up. Larger prospective studies are needed to define safety, effectiveness, and optimal dosing in neonates.

Förderung

  • Italian Ministry of Health

Zitieren

APA

Rose, D. U. D., Romano, V., Ronci, S., Maddaloni, C., Arena, R., Longo, D., Luciani, M., Braguglia, A., Dotta, A., Gallini, F., & Campi, F. (2026). Rivaroxaban Use for Central Nervous System Thrombotic Events in Neonates: A Case Series. Children, 13(11), 1611. https://doi.org/10.3390/children13111611

Vancouver

Rose DUD, Romano V, Ronci S, Maddaloni C, Arena R, Longo D, et al. Rivaroxaban Use for Central Nervous System Thrombotic Events in Neonates: A Case Series. Children. 2026;13(11):1611. doi:10.3390/children13111611

BibTeX
@article{Rose2026,
  author = {Rose, Domenico Umberto De and Romano, Valerio and Ronci, Sara and Maddaloni, Chiara and Arena, Roberta and Longo, Daniela and Luciani, Matteo and Braguglia, Annabella and Dotta, Andrea and Gallini, Francesca and Campi, Francesca},
  title = {Rivaroxaban Use for Central Nervous System Thrombotic Events in Neonates: A Case Series},
  journal = {Children},
  year = {2026},
  volume = {13},
  number = {11},
  pages = {1611},
  doi = {10.3390/children13111611}
}
Kostenlos starten →